This article is more than 5 years old. Information may no longer be current.
Top stories in hematology/oncology: Lonsurf prolongs survival, cancer treatment during pregnancy
Among the top stories in hematology/oncology is a trial comparing trifluridine and tipiracil with placebo for treatment of metastatic gastric cancer met its primary endpoint of OS. The number of women receiving cancer treatment during pregnancy has increased over recent decades, raising concerns about neonatal complications according to researchers in Europe. Other stories include research suggesting oncologists have room for improvement when prescribing cannabis for cancer-related symptoms, a debate over the use of telemedicine for the treatment of patients with hematologic malignancies, and updated guidelines surrounding the use of bisphosphonates for multiple myeloma.
Lonsurf prolongs survival in metastatic gastric cancer
A trial designed to compare trifluridine and tipiracil with placebo for treatment of metastatic gastric cancer met its primary endpoint of OS, according to the agent’s manufacturer. Read More.
Cancer treatment during pregnancy has increased, may cause neonatal complications
The proportion of women who received cancer treatment during pregnancy has increased significantly in recent decades, according to researchers in Europe. Read More.
‘Room for improvement’ exists in oncologists’ knowledge of medical marijuana
About half of oncologists reported they recommended cannabis for cancer-related symptoms, according to study findings published in Journal of Clinical Oncology. Read More.
Experts debate the use of telemedicine a s an option for the treatment of patients with hematologic malignancies?
A point-counterpoint examines the current role of telemedicine in managing patients with cancer and whether it is a viable option now or if more refinement of processes are needed. Read More.
ASCO updates guideline on use of bisphosphonates for multiple myeloma
An updated ASCO clinical practice guideline defines when to appropriately initiate treatment with bisphosphonates among patients with multiple myeloma. Read More.